IFC invests $16.5 mn in MedGenome to increase Covid-19 testing in India

International Finance Corporation, member of the World Bank Group, is investing $16.5 million in genetic diagnostics and research company MedGenome to increase access to Covid-19 testing in India

MedGenome Labs
MedGenome
Press Trust of India New Delhi
2 min read Last Updated : Jul 15 2021 | 12:55 PM IST

Don't want to miss the best from Business Standard?

International Finance Corporation, member of the World Bank Group, is investing USD 16.5 million (around Rs 123 crore) in genetic diagnostics and research company MedGenome to increase access to COVID-19 testing in India.

The partnership, apart from increasing the access to COVID-19 testing, will also support research to better help understand the virus, its variants and manage future outbreaks, IFC and MedGenome said in a statement on Thursday.

IFC's USD 16.5 million equity investment will support the expansion of MedGenome's diagnostic services as well as boost genomic data from South Asian populations, which can help provide valuable insights into complex diseases and help develop effective medical solutions for diverse populations, it added.

"With IFC's support, we will continue to expand our services across India, bringing tests directly to the communities most affected by the pandemic, and finding genetic variants that might be making some people more susceptible to severe COVID-19 infection and post-COVID illness, MedGenome Founder and Chairman Sam Santhosh said.

Fast, reliable and extensive testing is one of the most important steps to end the pandemic, he added.

"This investment will help increase access to reliable testing and monitoring of the virus, as well as identify life-saving treatments. Our overall aim is to help India strengthen its healthcare systems, build resilience, and ramp up recovery from the pandemic," IFC Managing Director Makhtar Diop said.

IFC's partnership with MedGenome comes at a critical time when India is facing an unprecedented crisis because of COVID-19, he added.

The investment in MedGenome is part of IFC's USD 4 billion Global Health Platform, which is providing financing to support the manufacturing and supply of vaccines, medical equipment, and therapeutics, as well as the logistics required to deliver vaccines and medications, it added.

IFC is a leading global development institution focused on the private sector in developing countries. It advances economic development and improves the lives of people by encouraging the growth of the private sector in developing countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IFCMedGenomeCoronavirus Tests

First Published: Jul 15 2021 | 12:55 PM IST

Next Story